Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Capital Expenditures (2017 - 2025)

Kiora Pharmaceuticals' Capital Expenditures history spans 4 years, with the latest figure at $78163.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 273.58% year-over-year to $78163.0; the TTM value through Dec 2025 reached $33563.0, up 174.53%, while the annual FY2025 figure was $110789.0, 1670.92% up from the prior year.
  • Capital Expenditures reached $78163.0 in Q4 2025 per KPRX's latest filing, up from $431.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $78163.0 in Q4 2025 to a low of -$45031.0 in Q4 2024.
  • Average Capital Expenditures over 3 years is $19485.6, with a median of $5746.0 recorded in 2021.
  • The largest YoY upside for Capital Expenditures was 273.58% in 2025 against a maximum downside of 273.58% in 2025.
  • A 3-year view of Capital Expenditures shows it stood at $5746.0 in 2021, then plummeted by 883.69% to -$45031.0 in 2024, then surged by 273.58% to $78163.0 in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Capital Expenditures are $78163.0 (Q4 2025), $431.0 (Q3 2025), and -$45031.0 (Q4 2024).